This year has seen more than its share of wildly successful investments, largely playing off of the pandemic — led by biotechnology stocks trying to treat, fight or prevent COVID-19 infections, and the (mostly technology) stocks that rode the accelerating adoption of remote work and play in the wake of “stay at home” and “social […]
↧